Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Johanna Friedl-Naderer, the Chief Commercial Officer of Dyne Therapeutics, Inc. (NASDAQ:DYN), recently sold shares of the company. According to a filing with the Securities and Exchange Commission, Friedl-Naderer disposed of 143 shares of common stock on March 13, 2025, at a price of $12.12 per share, totaling approximately $1,733. The transaction occurred as DYN shares trade near their 52-week low of $11.18, having declined about 48% year-to-date. InvestingPro analysis suggests the stock is currently undervalued, with analysts maintaining a strong buy consensus.
The transaction was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) granted on December 4, 2024. This sale was part of an automatic plan and did not represent a discretionary trade by Friedl-Naderer. Following the transaction, she retains ownership of 96,057 shares, which include 93,838 unvested RSUs. Track insider transactions and access comprehensive financial metrics with InvestingPro, where you’ll find exclusive insights on company valuations and market trends.
In other recent news, Dyne Therapeutics has been the focus of several analyst updates and strategic developments. The company concluded 2024 with a robust cash reserve of approximately $642.3 million and further bolstered its financial position by raising $140.6 million through an at-the-market share issuance, bringing its pro forma cash position to about $783 million. Oppenheimer has maintained an Outperform rating with a $60 price target, emphasizing the significance of the Fast Track Designation granted by the FDA for DYNE-101, which could expedite the review process for treating myotonic dystrophy type 1 (DM1). Piper Sandler adjusted its price target to $48 while keeping an Overweight rating, highlighting recent funding moves and clinical progress.
H.C. Wainwright revised its price target for Dyne Therapeutics to $46, retaining a Buy rating, based on recent clinical data and the potential for accelerated approval pathways. Scotiabank (TSX:BNS) initiated coverage with a Sector Outperform rating and a $50 price target, noting the advantageous entry point for investors due to current market conditions. BMO Capital Markets also initiated coverage with an Outperform rating and a $50 price target, focusing on Dyne’s advancements in treating neuromuscular disorders. Analysts are closely watching upcoming clinical milestones, including potential accelerated approval submissions in 2026, which could significantly impact Dyne’s market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.